Clinical trials recruiting for Solid Tumors
17
Recruiting trials
36
US states with sites
28
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 7 |
| Florida | 6 |
| Massachusetts | 6 |
| New York | 6 |
| Texas | 6 |
| North Carolina | 5 |
| Pennsylvania | 5 |
| Colorado | 4 |
| Maryland | 4 |
| Minnesota | 4 |
| Washington | 4 |
| Georgia | 3 |
Top cities
Boston, Massachusetts 6New York, New York 6Houston, Texas 5Philadelphia, Pennsylvania 4San Francisco, California 4Atlanta, Georgia 3Baltimore, Maryland 3Dallas, Texas 3Los Angeles, California 3Madison, Wisconsin 3
Self-screener
Recruiting trials
- A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
- A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- CTS2190 Phase I /II Clinical Study in Patients
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
- JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Related conditions
Trials recruiting for Solid Tumors often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Pancreatic cancer 870Non-small cell lung cancer 507Colorectal cancer 1359Breast cancer 2239Melanoma 487Gastric cancer 91Urothelial Carcinoma 29Triple Negative Breast Cancer, TNBC 35Triple-negative breast cancer 138
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Solid Tumors trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.